|
49 Companies |
|
58 Products |
|
58 Products |
|
60 Mechanisms of Action |
|
0 Trials |
|
197 News |
|
| 1234» |
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination, Metastases: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer (clinicaltrials.gov) - Jan 18, 2019
P1, N=19, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision.
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 1, 2018
P2, N=43, Completed, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017
- | cyclophosphamide / Generic mfg.
Trial completion: Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma (clinicaltrials.gov) - Jun 15, 2018
P1/2, N=44, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Nov 20, 2017
P1, N=1, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- | Phase classification, Trial primary completion date: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - Oct 6, 2017
P2, N=8, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 Phase classification: P1/2 --> P2 | Trial primary completion date: Jun 2015 --> May 2014
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors (clinicaltrials.gov) - Sep 29, 2017
P2, N=1, Terminated, Sponsor: Burzynski Research Institute
Phase classification: P1/2 --> P2 | Trial primary completion date: Jun 2015 --> May 2014 N=40 --> 1 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion, Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 17, 2017
P1, N=50, Completed, Sponsor: St. Jude Children's Research Hospital
N=40 --> 1 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 1, 2017
P1, N=113, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014 N=74 --> 113
- ||| Talzenna (talazoparib) / Pfizer
Trial completion, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Jul 18, 2017
P1, N=74, Completed, Sponsor: Medivation, Inc.
N=74 --> 113 Active, not recruiting --> Completed
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 14, 2017
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
- | dactinomycin / Generic mfg., vincristine / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Evaluating Dactinomycin and Vincristine in Young Patients With Cancer (clinicaltrials.gov) - May 17, 2017
P=N/A, N=158, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jun 2016
- | plerixafor / Generic mfg.
Trial completion, Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - May 16, 2017
P1/2, N=46, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jun 2016 Active, not recruiting --> Completed | N=30 --> 46
- | Biomarker, Trial primary completion date: Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma (clinicaltrials.gov) - May 8, 2017
P=N/A, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed | N=30 --> 46 Trial primary completion date: Feb 2017 --> Apr 2016
- | Trial completion, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=9, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2017 --> Apr 2016 Active, not recruiting --> Completed
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Jan 10, 2017
P1, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=39 --> 29 | Trial primary completion date: Dec 2016 --> Jun 2016
- melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 6, 2016
P1, N=0, Withdrawn, Sponsor: University of Louisville
Active, not recruiting --> Completed | N=39 --> 29 | Trial primary completion date: Dec 2016 --> Jun 2016 N=10 --> 0 | Recruiting --> Withdrawn
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Oct 21, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
N=10 --> 0 | Recruiting --> Withdrawn N=46 --> 30
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=46 --> 30 Trial primary completion date: Jun 2015 --> Dec 2016
- decitabine / Generic mfg.
Trial completion: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=19, Completed, Sponsor: University of Louisville
Trial primary completion date: Jun 2015 --> Dec 2016 Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 18
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment closed, Enrollment change: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 19, 2016
P1, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=30 --> 18 Recruiting --> Active, not recruiting | N=75 --> 50
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Jul 15, 2016
P1, N=39, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=75 --> 50 N=29 --> 39 | Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=1650, Completed, Sponsor: Children's Oncology Group
N=29 --> 39 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | Biomarker, Trial completion, Trial primary completion date: Biomarker in Tissue Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=40, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- NN1213 / Novo Nordisk
Trial completion, Enrollment change, Metastases: Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Jun 21, 2016
P1, N=27, Completed, Sponsor: O'Dorisio, M S
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Recruiting --> Completed | N=35 --> 27
- ||| Trial completion, Trial primary completion date: Study of Tumor Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 19, 2016
P=N/A, N=200, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | N=35 --> 27 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Biomarker, Enrollment change, Trial termination: Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma (clinicaltrials.gov) - May 10, 2016
P=N/A, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 N=24 --> 6 | Recruiting --> Terminated; Slow accrual and lack of funding
- Trial completion, Enrollment change: Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=950, Completed, Sponsor: University Hospital Muenster
N=24 --> 6 | Recruiting --> Terminated; Slow accrual and lack of funding Recruiting --> Completed | N=2200 --> 950
- Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Apr 21, 2016
P1, N=28, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=2200 --> 950 Recruiting --> Active, not recruiting | N=39 --> 28
- Trial termination: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - Mar 16, 2016
P1/2, N=8, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=39 --> 28 Completed --> Terminated; Study was closed to enrollment before dose level one was completed.
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Mar 10, 2016
P1, N=74, Active, not recruiting, Sponsor: Medivation, Inc.
Completed --> Terminated; Study was closed to enrollment before dose level one was completed. N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Enrollment change, Trial primary completion date, Metastases: Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma (clinicaltrials.gov) - Mar 10, 2016
P2, N=12, Completed, Sponsor: Massachusetts General Hospital
N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015 Active, not recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Apr 2014 --> Jan 2014
- decitabine / Generic mfg.
Enrollment closed, Enrollment change: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Feb 10, 2016
P1, N=19, Active, not recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Apr 2014 --> Jan 2014 Recruiting --> Active, not recruiting | N=15 --> 19
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Feb 4, 2016
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | N=15 --> 19 Trial primary completion date: Jun 2016 --> Jun 2017
- Enrollment change, Trial withdrawal: Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients (clinicaltrials.gov) - Jan 15, 2016
P3, N=0, Withdrawn, Sponsor: Children's Cancer Hospital Egypt 57357
Trial primary completion date: Jun 2016 --> Jun 2017 N=150 --> 0 | Recruiting --> Withdrawn
- Trial completion, Enrollment change, Trial primary completion date: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma (clinicaltrials.gov) - Jan 4, 2016
P2, N=13, Completed, Sponsor: City of Hope Medical Center
N=150 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Mar 2016 --> Sep 2014
- Trial completion, Enrollment change: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=20, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Mar 2016 --> Sep 2014 Active, not recruiting --> Completed | N=50 --> 20
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Nov 24, 2015
P1, N=113, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Active, not recruiting --> Completed | N=50 --> 20 N=85 --> 113 | Trial primary completion date: Dec 2014 --> Jan 2016
- | arsenic trioxide / Generic mfg.
Trial completion, Metastases: Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors (clinicaltrials.gov) - Nov 24, 2015
P2, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=85 --> 113 | Trial primary completion date: Dec 2014 --> Jan 2016 Suspended --> Completed
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Suspended --> Completed N=18 --> 30
- Enrollment closed, Trial primary completion date: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=18 --> 30 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015
- Trial completion, Trial primary completion date, Metastases: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Aug 26, 2015
P1, N=33, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- melphalan / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Aug 21, 2015
P1, N=10, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Trial primary completion date: Oct 2015 --> Oct 2016
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=15, Recruiting, Sponsor: University of Louisville
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 18, 2015
P2, N=43, Active, not recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Trial primary completion date: Aug 2015 --> Aug 2016 Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 14, 2015
P2, N=43, Completed, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Completed
- || humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- | Vaxira (racotumomab) / Eurofarma, Recombio
Trial completion: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - Jun 29, 2015
P1, N=15, Completed, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed